Jacob Berchuck

Medical Oncologist and Physician-Scientist at @EmoryMedicine & @WinshipAtEmory. Learn more about our work @

[Jacob Berchuck @jberchuck]

🚀 Excited to share that I’ve joined @EmoryMedicine & @WinshipAtEmory to launch The Berchuck Lab.

Our research is focused on using liquid biopsy to improve outcomes for people living with cancer.

We’re hiring for several key roles!

Learn more & apply: https://t.co/Sw6sqMvguX

[Sylvan Baca MD PhD (Hiring!) @SylvanBacaLab]

Excited to share our latest preprint by Alexis Yang and Gary Lee, in collab with the @jberchuck lab: https://t.co/cb3pRjketO. We found that transcription of enhancers (a mark of activation) causes distinct fragmentation patterns in #cfDNA.

[Jacob Berchuck @jberchuck]

🧬 Our Play-Doh vision for a futuristic prostate cancer therapy at the @PCF_Science Young Investigator Retreat… an all-in-one CAR-T model targeting PSMA, STEAP2, CD46, KLK2, and B7-H3 💪 #PCFRetreat25 #table12

[Jordan Ciuro, MD @jordanciuro]

🚨 Check out our new post in @ASCO Daily News

🔎Exploring emerging paradigms transforming metastatic hormone-sensitive prostate cancer care - from novel systemic therapies to personalized strategies. A shift in practice is underway!!
@jberchuck @EHeath4100 & Dr. Brad Carthon

🔗 https://t.co/NYmLlQwZEV

#ProstateCancer #Oncology #ASCO25 #mHSPC @WinshipAtEmory #ASCODailyNews @GUOncologyNow @OncoAlert @TargetedOnc

[Jacob Berchuck @jberchuck]

🚨 Excited to share our manuscript in @Nature_NPJ highlighting the expanding role of liquid biopsy to detect clinically actionable non-genomic mechanisms of therapeutic resistance.

Led by @KarlSemaan @RashadNawfal with collaborators @SylvanBacaLab @DrChoueiri #MattFreedman.

[Rashad Nawfal, MD @RashadNawfal]

1/ Happy to share our latest piece in @Nature_NPJ precision oncology: "Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer".

Work co-led with @KarlSemaan with great mentorship from @Jberchuck @SylvanBacaLab #MattFreedman @DrChoueiri

https://t.co/dN5PeZZwhE

[UroToday.com @urotoday]

Plasma epigenomic profiling to reveal molecular correlates of response and resistance to 177Lu-PSMA-617 in #mCRPC. Presentation by @jberchuck @EmoryMedicine. #ASCO25 written coverage by @RKSayyid @USC > https://t.co/d6FWRFHNGZ @ASCO

[Winship Cancer Institute of Emory University @WinshipAtEmory]

Winship medical oncologist Jacob E. Berchuck, MD recently spoke with @targetedonc on how a new epigenomic platform may influence the accessibility of prostate-specific membrane antigen-based therapies. ➡️ https://t.co/5EPsD0eTYg

[Urology Times @UrologyTimes]

Data presented at #ISLB24 suggest that epigenomic cfDNA may accurately assess PSMA expression and predict Lu-PSMA response in mCRPC. @jberchuck @emory_urology #pcsm
https://t.co/JfiuvR5KnC

[Jacob Berchuck @jberchuck]

Honored to be awarded best poster at the @isliquidbiopsy #ISLB24 Annual Congress for our work using a novel epigenomic liquid biopsy platform to detect PSMA expression and predict Pluvicto response in mCRPC.

CC: fantastic collaborators @PrafulRavi1 @HJacene @Precede_Bio

[Jacob Berchuck @jberchuck]

Thank you @isliquidbiopsy for the opportunity to speak on the potential of liquid biopsies for early cancer detection at #ISLB24.

Congrats to @ChristianRolfo and co for organizing a fantastic conference!

[Alicia Madison @apmadison5]

Session on liquid biopsy for early cancer detection #ISLB24
@ChristianRolfo @ValsamoA @jberchuck and great to hear about hereditary cancer advancements @PughLab

[Aadel Chaudhuri, MD PhD @aadel_chaudhuri]

Fantastic @CCR_AACR Translations piece from @jberchuck & colleagues on our recent @CCR_AACR paper uncovering a stemness signature enriched in cfDNA in lethal AR-altered prostate cancer patients.

@pradeep198212 @MayoRadOnc @MayoCancerCare @MayoClinic

https://t.co/Bvhp54J0Lo

[Prostate Cancer Foundation @PCFnews]

📊 Revolutionary approach: Analyzing cell-free DNA to track PSMA expression in real-time. Dr. Jake Berchuck (@jberchuck) discusses how this could transform treatment decisions in prostate cancer.

Watch the complete discussion on @urotoday: https://t.co/sducE8whNc

[UroToday.com @urotoday]

Novel epigenomic liquid biopsy detects PSMA expression in #ProstateCancer. @jberchuck @WinshipAtEmory and Oliver Sartor, MD @MayoClinic dive into this cutting-edge epigenomic liquid biopsy platform that uses cell-free DNA to infer PSMA expression. This novel assay shows a strong correlation with PSMA PET scans, offering a non-invasive, real-time tool for monitoring tumor drug target expression. #WatchNow > https://t.co/vdrJdYPDeB

[Prostate Cancer Foundation @PCFnews]

Challenging prostate cancer subtypes like liver metastases and neuroendocrine #prostatecancer may ultimately benefit from more precise treatment approaches, thanks to innovative liquid biopsy technology.

@sartor_oliver & @jberchuck discuss on @urotday- https://t.co/n6Bqp3hcNL

[Targeted Oncology @TargetedOnc]

WATCH: Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented at #ESMO24. @jberchuck @EmoryMedicine @WinshipAtEmory

https://t.co/hnHI1eJq6y

[Jacob Berchuck @jberchuck]

7/ 🎯 We conclude that the SigMA HRD mutational signature could help refine the population of mCRPC patients who may benefit from PARPi. Larger studies are needed for further validation. Stay tuned!

[Jacob Berchuck @jberchuck]

1/ 🔈Excited to share our latest publication “A panel-based mutational signature of HRD associates with response to PARP inhibition in mCRPC” led by #danielboiarsky @aloktewar @dcgulhan.

🧵Below…

📄Read the full paper here: https://t.co/yxqVCHYZim

[Jacob Berchuck @jberchuck]

6/ 👴🏻 We highlight a patient lacking an HR gene alteration but classified as HRD by SigMA who experienced a 64% reduction in PSA and 11-month rPFS on olaparib, suggesting the potential clinical utility of SigMA to identify PARPi responders in mCRPC.